Skye Becomes a Shell for Redx: $125 Million Deal Hands Control to UK Fibrosis Company
Skye Bioscience acquires Redx Pharma via UK scheme of arrangement. Combined company Fibrx focuses on RXC008 for Crohn’s fibrosis. Skye holders get only 5.38%.
/ 3 items
#SKYE↓
Skye Bioscience Nimacimab Study Fails Primary Endpoint
Skye Bioscience reports mixed results for its weight-loss drug nimacimab: it failed alone due to suboptimal dosing, but adding it to semaglutide (Wegovy/Ozempic) resulted in significant extra weight loss without increasing common stomach or mental side effects.
Excitement Builds for Skye Bioscience's Potential Weight Loss Game-Changer
Skye Bioscience's promising, safe weight loss drug, nimacimab, earned a "Buy" rating and $20 price target from analysts.